Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC
Status:
Recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
This study is an open-label, multicentre, Phase 1b trial designed to determine the safety,
tolerability, efficacy, PK, pharmacodynamics (PD) and proof-of-concept of OMO-103 in
combination with the standard regimen gemcitabine/nab-paclitaxel in patients with metastatic
pancreatic cancer who are treatment-naïve in the advanced disease setting.